Cargando…

Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis

INTRODUCTION: The introduction of tumor necrosis factor-alpha (TNF-α) antagonists has substantially improved patient’s clinical outcome in rheumatoid arthritis (RA). However, nearly 20% to 40% of RA patients do not respond to anti-TNF-α treatment strategies. To identify valid predictors of TNF-α ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Blaschke, Sabine, Rinke, Kathinka, Maring, Michael, Flad, Thomas, Patschan, Susann, Jahn, Olaf, Mueller, Claudia A, Mueller, Gerhard A, Dihazi, Hassan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383078/
https://www.ncbi.nlm.nih.gov/pubmed/25884688
http://dx.doi.org/10.1186/s13075-015-0553-1
_version_ 1782364675942383616
author Blaschke, Sabine
Rinke, Kathinka
Maring, Michael
Flad, Thomas
Patschan, Susann
Jahn, Olaf
Mueller, Claudia A
Mueller, Gerhard A
Dihazi, Hassan
author_facet Blaschke, Sabine
Rinke, Kathinka
Maring, Michael
Flad, Thomas
Patschan, Susann
Jahn, Olaf
Mueller, Claudia A
Mueller, Gerhard A
Dihazi, Hassan
author_sort Blaschke, Sabine
collection PubMed
description INTRODUCTION: The introduction of tumor necrosis factor-alpha (TNF-α) antagonists has substantially improved patient’s clinical outcome in rheumatoid arthritis (RA). However, nearly 20% to 40% of RA patients do not respond to anti-TNF-α treatment strategies. To identify valid predictors of TNF-α antagonist response in RA, serum proteome profiles from responders (R) and non-responders (NR) to etanercept, a soluble recombinant TNF-α receptor/IgG Fc fusion protein receptor, were compared in a prospective cohort study. METHODS: In this clinical study 50 RA patients with inadequate response to conventional DMARDs were included and treated with etanercept. The primary efficacy endpoint was response according to the European League against Rheumatism (EULAR) improvement criteria. Serum samples collected prior to initiation and after six months of etanercept therapy were cleared of the most abundant major proteins by immunoaffinity chromatography. After separation by two-dimensional differential gel electrophoresis (2D-DIGE) and identification by mass spectrometry (MS) data were validated by Western blot analysis. RESULTS: After six months of etanercept treatment 62% (n = 31) of RA patients achieved response. Haptoglobin-α1 (Hp-α1) and -α2 (Hp-α2) and vitamin D-binding protein (VDBP) were found to be significantly upregulated in responder sera (P ≤0.02) at study entry. In contrast, apolipoprotein C-III (ApoC-III) showed significantly higher levels in non-responders (P = 0.0162). At study end ApoA-II, Hp-α1, Hp-α2 and VDBP were identified to be expressed at significantly higher levels (P <0.05) in responder sera. CONCLUSIONS: By application of clinical proteomics in immunodepleted sera we could identify and validate for the first time Hp-α1, -α2, VDBP and ApoC-III as potential biomarkers for prediction of etanercept drug response in RA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-015-0553-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4383078
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43830782015-04-03 Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis Blaschke, Sabine Rinke, Kathinka Maring, Michael Flad, Thomas Patschan, Susann Jahn, Olaf Mueller, Claudia A Mueller, Gerhard A Dihazi, Hassan Arthritis Res Ther Research Article INTRODUCTION: The introduction of tumor necrosis factor-alpha (TNF-α) antagonists has substantially improved patient’s clinical outcome in rheumatoid arthritis (RA). However, nearly 20% to 40% of RA patients do not respond to anti-TNF-α treatment strategies. To identify valid predictors of TNF-α antagonist response in RA, serum proteome profiles from responders (R) and non-responders (NR) to etanercept, a soluble recombinant TNF-α receptor/IgG Fc fusion protein receptor, were compared in a prospective cohort study. METHODS: In this clinical study 50 RA patients with inadequate response to conventional DMARDs were included and treated with etanercept. The primary efficacy endpoint was response according to the European League against Rheumatism (EULAR) improvement criteria. Serum samples collected prior to initiation and after six months of etanercept therapy were cleared of the most abundant major proteins by immunoaffinity chromatography. After separation by two-dimensional differential gel electrophoresis (2D-DIGE) and identification by mass spectrometry (MS) data were validated by Western blot analysis. RESULTS: After six months of etanercept treatment 62% (n = 31) of RA patients achieved response. Haptoglobin-α1 (Hp-α1) and -α2 (Hp-α2) and vitamin D-binding protein (VDBP) were found to be significantly upregulated in responder sera (P ≤0.02) at study entry. In contrast, apolipoprotein C-III (ApoC-III) showed significantly higher levels in non-responders (P = 0.0162). At study end ApoA-II, Hp-α1, Hp-α2 and VDBP were identified to be expressed at significantly higher levels (P <0.05) in responder sera. CONCLUSIONS: By application of clinical proteomics in immunodepleted sera we could identify and validate for the first time Hp-α1, -α2, VDBP and ApoC-III as potential biomarkers for prediction of etanercept drug response in RA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-015-0553-1) contains supplementary material, which is available to authorized users. BioMed Central 2015-03-06 2015 /pmc/articles/PMC4383078/ /pubmed/25884688 http://dx.doi.org/10.1186/s13075-015-0553-1 Text en © Blaschke et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Blaschke, Sabine
Rinke, Kathinka
Maring, Michael
Flad, Thomas
Patschan, Susann
Jahn, Olaf
Mueller, Claudia A
Mueller, Gerhard A
Dihazi, Hassan
Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis
title Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis
title_full Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis
title_fullStr Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis
title_full_unstemmed Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis
title_short Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis
title_sort haptoglobin-α1, -α2, vitamin d-binding protein and apolipoprotein c-iii as predictors of etanercept drug response in rheumatoid arthritis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383078/
https://www.ncbi.nlm.nih.gov/pubmed/25884688
http://dx.doi.org/10.1186/s13075-015-0553-1
work_keys_str_mv AT blaschkesabine haptoglobina1a2vitamindbindingproteinandapolipoproteinciiiaspredictorsofetanerceptdrugresponseinrheumatoidarthritis
AT rinkekathinka haptoglobina1a2vitamindbindingproteinandapolipoproteinciiiaspredictorsofetanerceptdrugresponseinrheumatoidarthritis
AT maringmichael haptoglobina1a2vitamindbindingproteinandapolipoproteinciiiaspredictorsofetanerceptdrugresponseinrheumatoidarthritis
AT fladthomas haptoglobina1a2vitamindbindingproteinandapolipoproteinciiiaspredictorsofetanerceptdrugresponseinrheumatoidarthritis
AT patschansusann haptoglobina1a2vitamindbindingproteinandapolipoproteinciiiaspredictorsofetanerceptdrugresponseinrheumatoidarthritis
AT jahnolaf haptoglobina1a2vitamindbindingproteinandapolipoproteinciiiaspredictorsofetanerceptdrugresponseinrheumatoidarthritis
AT muellerclaudiaa haptoglobina1a2vitamindbindingproteinandapolipoproteinciiiaspredictorsofetanerceptdrugresponseinrheumatoidarthritis
AT muellergerharda haptoglobina1a2vitamindbindingproteinandapolipoproteinciiiaspredictorsofetanerceptdrugresponseinrheumatoidarthritis
AT dihazihassan haptoglobina1a2vitamindbindingproteinandapolipoproteinciiiaspredictorsofetanerceptdrugresponseinrheumatoidarthritis